Evidence map›Paper›PMID 41243277›Full record

ArticleCancer biology & therapy2025

Yanzi Qin, Hongfei Ci, Zhaoyi Wang, Yandie Zhang, Xifeng Xu, Qiang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanzi QinDepartment of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Hongfei CiDepartment of Pathology, Bengbu Medical University, Bengbu, China.
Zhaoyi WangDepartment of Pathology, Bengbu Medical University, Bengbu, China.
Yandie ZhangDepartment of Pathology, Bengbu Medical University, Bengbu, China.
Xifeng XuDepartment of Pathology, Bengbu Medical University, Bengbu, China.
Qiang WuDepartment of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0009-0002-0501-9491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAryl hydrocarbon receptor nuclear transporter-like 2 (ARNTL2) can bind to clock circadian regulator (CLOCK) to regulate gene expression and is abnormally expressed in various cancers. Nevertheless, its effects on esophageal cancer (ESCC) are unclear. This work can uncover the intriguing mechanism of ARNTL2 in ESCC.

methodsMalignant phenotypes including cell proliferation, invasion, migration, and epithelial mesenchymal transition (EMT), were investigated. We established a BALB/c nude mouse (5-6 weeks) model with ESCC to verify the influence of ARNTL2/ANXA2/C-MYC axis. ESCC tissues (

resultsCompared to adjacent normal tissues, ESCC tissues developed the significant increase

conclusionARNTL2 activated the transcription of

Indexed as

Annexin A2Esophageal NeoplasmsProto-Oncogene Proteins c-mycAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CMice, NudeAnnexin A2ANXA2 protein, humanMYC protein, humanProto-Oncogene Proteins c-mycannexin 2aryl hydrocarbon receptor nuclear transporter-like 2C-MYCEsophageal cancer

Identifiers

PMID41243277
PMCPMC12629337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.